Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Smallpox

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.

Chickenpox

Chickenpox

Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Genital Herpes

Genital Herpes

Genital herpes is a sexually transmitted infection primarily caused by herpes simplex virus type 2 (HSV-2), though herpes simplex virus type 1 (HSV-1) is increasingly implicated in genital infections, particularly among younger populations. Transmission occurs mainly through sexual contact, with asymptomatic viral shedding serving as a major route of spread. This characteristic makes HSV-2 difficult to control at a population level, as individuals may unknowingly transmit the virus even in the...

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Factorial design for improving influenza vaccination among employees of a large health system.

Infection control and hospital epidemiology·2009

Same author

Recent changes in influenza vaccination recommendations, 2007.

The Journal of family practice·2007

Same author

Routine vaccines across the life span, 2007.

The Journal of family practice·2007

Same author

Vaccines for persons at high risk, 2007.

The Journal of family practice·2007

Same author

Vaccine schedules and procedures, 2007.

The Journal of family practice·2007

Same author

Addressing immunization barriers, benefits, and risks.

The Journal of family practice·2007

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

HPV vaccine and its recommendations, 2007.

Richard Kent Zimmerman¹

¹Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

The Journal of Family Practice

|February 3, 2007

Summary

The quadrivalent human papillomavirus (HPV) vaccine is highly effective in preventing cervical cancer and genital warts. Routine vaccination is recommended for females aged 11-12, with catch-up options available.

Area of Science:

Immunology
Vaccinology
Oncology

Background:

Cervical cancer and genital warts are significant public health concerns.
Human papillomavirus (HPV) is the primary cause of these conditions.
A quadrivalent vaccine targeting high-risk HPV types (16, 18) and low-risk types (6, 11) has been developed.

Purpose of the Study:

To evaluate the efficacy and safety of the quadrivalent HPV vaccine.
To establish vaccination recommendations for disease prevention.

Main Methods:

Clinical trials assessing vaccine efficacy against HPV-related lesions and warts.
Monitoring of adverse reactions post-vaccination.

Main Results:

The vaccine demonstrated 95%-100% efficacy against cervical intraepithelial neoplasia and adenocarcinoma in situ.

Related Experiment Videos

Last Updated: Jul 17, 2026

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

99% efficacy was observed against vaccine-type genital warts.

Common adverse reactions included local injection site pain and swelling.

Conclusions:

The quadrivalent HPV vaccine is a safe and highly effective tool for preventing HPV-related cancers and genital warts.
Routine vaccination is recommended for females aged 11-12 years.
Catch-up vaccination is advised for unvaccinated females up to age 26, with discretionary vaccination for younger girls.